IntroductionHereditary angioedema (HAE) is characterized by recurrent subcutaneously
and/or submucosally localized edematous swellings. The first symptoms often appear
in childhood, and they may become more frequent and severe in puberty. Since the appearance
of HAE attacks is unpredictable regarding the localization and the frequency, the
attacks put a significant burden on the patients and crucially impacts their quality
of life.Areas coveredThis review article analyzes the safety data acquired from the
clinical trials conducted with the currently available medicinal products for the
prophylactic treatment of hereditary angioedema due to C1 inhibitor deficiency and
the safety data of observatory studies based on clinical practice. A review of the
published literature was conducted using the PubMed database, clinical trials from
ClinicalTrials.gov, and abstracts published at scientific conferences.Expert opinionThe
currently available therapeutic products have a good safety and efficiency profile
and the international guidelines recommend them as first-line treatments. The choice
should be made based on the evaluation of the availability and the preference of the
patient.
